Aptahem AB (XSAT:APTA) Cyclically Adjusted FCF per Share: kr-37.90 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:APTA Aptahem AB XSAT:APTA
29 GF Score
Price kr0.34
! 1 Warning Sign
View Full Analysis

What is Aptahem AB Cyclically Adjusted FCF per Share?

Aptahem AB XSAT:APTA -10.73% 29 Cyclically Adjusted FCF per Share is kr-37.90 as of Jun. 2026. GuruFocus rates XSAT:APTA with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Aptahem AB's adjusted free cash flow per share for the three months ended in Jun. 2026 was kr-0.067. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-37.90 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-09-17), Aptahem AB's current stock price is kr0.341. Aptahem AB's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was kr-37.90. Aptahem AB's Cyclically Adjusted Price-to-FCF of today is .


Aptahem AB  (XSAT:APTA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Aptahem AB Cyclically Adjusted FCF per Share Related Terms


Aptahem AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Aptahem AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aptahem AB Cyclically Adjusted FCF per Share Chart

Aptahem AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -42.49 -38.66 -31.73

Aptahem AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -46.20 -44.72 -42.36 -40.25 -37.90

XSAT:APTA vs VRTX, REGN, MRNA: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Aptahem AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptahem AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptahem AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Aptahem AB's Cyclically Adjusted Price-to-FCF falls into.


XSAT:APTA
29GF Score
Aptahem AB XSAT:APTA
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aptahem AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aptahem AB's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.067/134.6100*134.6100
=-0.067

Current CPI (Jun. 2026) = 134.6100.

Aptahem AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -10.119 101.138 -13.468
201612 -22.323 102.022 -29.454
201703 -12.540 102.022 -16.546
201706 -13.630 102.752 -17.856
201709 -52.243 103.279 -68.092
201712 -13.560 103.793 -17.586
201803 -26.188 103.962 -33.908
201806 -25.317 104.875 -32.495
201809 -9.215 105.679 -11.738
201812 0.339 105.912 0.431
201903 -10.658 105.886 -13.549
201906 -4.950 106.742 -6.242
201909 -4.188 107.214 -5.258
201912 -8.369 107.766 -10.454
202003 -0.407 106.563 -0.514
202006 -4.828 107.498 -6.046
202009 -6.042 107.635 -7.556
202012 -11.777 108.296 -14.639
202103 -14.473 108.360 -17.979
202106 -10.278 108.928 -12.701
202109 -3.036 110.338 -3.704
202112 -4.177 112.486 -4.999
202203 12.328 114.825 14.452
202206 -8.311 118.384 -9.450
202209 -0.546 122.296 -0.601
202212 1.087 126.365 1.158
202303 -1.868 127.042 -1.979
202306 -0.893 129.407 -0.929
202309 -2.528 130.224 -2.613
202312 0.267 131.912 0.272
202403 -1.651 132.205 -1.681
202406 -31.916 132.716 -32.371
202409 -0.104 132.304 -0.106
202412 -0.226 132.987 -0.229
202503 -0.167 132.825 -0.169
202506 -0.115 133.699 -0.116
202509 -0.382 133.480 -0.385
202512 0.179 133.380 0.181
202603 -0.050 133.550 -0.050
202606 -0.067 134.610 -0.067

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-37.90 mean?
Aptahem AB (XSAT:APTA) has a Cyclically Adjusted FCF per Share of kr-37.90 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Aptahem AB and its competitors.
Is Aptahem AB's Cyclically Adjusted FCF per Share too high?
Aptahem AB's current Cyclically Adjusted FCF per Share is kr-37.90. Overall, Aptahem AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aptahem AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Aptahem AB's Cyclically Adjusted FCF per Share of kr-37.90 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Aptahem AB and its competitors. Aptahem AB's current Cyclically Adjusted FCF per Share is kr-37.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptahem AB stock overvalued right now?
Aptahem AB (XSAT:APTA) has a current Cyclically Adjusted FCF per Share of kr-37.90. The current Cyclically Adjusted FCF per Share is kr-37.90. Aptahem AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Aptahem AB (XSAT:APTA), the current Cyclically Adjusted FCF per Share is kr-37.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aptahem AB Business Description

Address Norra Vallgatan 58, Malmo, SWE, 211 22
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.
29GF Score

Get the complete analysis for XSAT:APTA

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.34
Price